• DS-1040 inhibits the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa).
Essentials
• DS-1040 inhibits the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa).
• Infusion of DS-1040 was safe and well tolerated in healthy young and elderly subjects.
• DS-1040 substantially decreased TAFIa activity but had no impact on bleeding time.
• DS-1040 may provide an option of safer thrombolytic therapy.
Summary. Background: Current treatments for acute ischemic stroke and venous thromboembolism, such as recombinant tissue-type plasminogen activator and thrombectomy, are limited by a narrow time window and the risk of bleeding. DS-1040 is a novel low molecular weight compound that inhibits the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa), and was developed as a fibrinolysis enhancer for the treatment of thromboembolic diseases. Objectives: This first-inhuman, randomized, placebo-controlled, three-part, phase 1 study was conducted to evaluate the safety, pharmacokinetics and pharmacodynamics of DS-1040 in healthy subjects. Subjects/Methods: Young (18-45 years) or elderly (65-75 years) subjects (N = 103) were randomized to receive single ascending doses of DS-1040 ranging from 0.1 mg to 40 mg, or placebo, administered either as a 0.5-h intravenous infusion or as a 24-h continuous infusion. Results: All doses of DS-1040 were tolerated, and no serious adverse events (AEs) or discontinuations resulting from AEs occurred during the study. Bleeding time remained within the normal range for all doses tested in all subjects. Plasma exposure of DS-1040 increased proportionally with increase in dose. Elderly subjects had higher exposures to DS-1040 and prolonged elimination times, probably because of decreased renal clearance. DS-1040 caused a substantial dose-dependent and time-dependent decrease in TAFIa activity and in 50% clot lysis time. The levels of D-dimer, indicative of endogenous fibrinolysis, increased in some individuals following DS-1040 treatment. No effects of DS-1040 on
Introduction
Thromboembolic diseases, such as acute ischemic stroke (AIS) and venous thromboembolism (VTE), constitute a serious public health concern [1] [2] [3] [4] [5] . Current therapy for AIS focuses on rapid revascularization of occluded blood vessels, followed by risk reduction and secondary prevention [6] . Thrombolysis with intravenous recombinant tissue-type plasminogen activator (rt-PA) is the current mainstay of AIS therapy [7, 8] , but administration of intravenous rt-PA is associated with a risk of intracerebral hemorrhage [9, 10] and possible neurotoxicity [11] . Another treatment option, intra-arterial thrombectomy, also has several limitations. It can be performed only in patients with a large vessel clot, is recommended to be completed within 6 h of stroke onset, and may be complicated by secondary embolization into new vascular territories [12, 13] . Thus, only a fraction of AIS patients can receive rt-PA or thrombectomy treatment and achieve prompt and stable vessel recanalization. Therefore, new treatments are needed for patients who are not eligible for rt-PA and thrombectomy (i.e. patients with less severe neurologic deficits at presentation, those with a higher risk of bleeding, or those arriving in emergency rooms/ settings after the early hours of symptom onset).
Similar concerns apply to VTE. Current treatment and prevention of VTE includes either parenteral or oral anticoagulation [14, 15] , as well as catheter-directed thrombectomy and rt-PA in patients with massive pulmonary embolism [6, 13, 16] . However, residual clot, recurrent VTE and long-term complications such as post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension are not fully addressed with current therapy [15] .
Endogenous fibrinolysis is initiated upon conversion of the proenzyme plasminogen to plasmin through the action of tissue-type plasminogen activator (t-PA) [15] . When plasmin cleaves fibrin, the cleavage products exposing C-terminal lysine residues can bind both plasminogen and t-PA, thus propagating fibrinolysis. Fibrinolysis is negatively regulated by several proteins, including the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa). Upon activation by thrombin, thrombinthrombomodulin complex, or plasmin, TAFIa removes lysine residues at the C-terminal of fibrin cleavage products, and thereby inhibits fibrinolysis (Fig. 1) [17] .
Thus far, TAFIa has no known physiologic inhibitor. DS-1040 is a novel low molecular weight (< 500 g mol À1 ) imidazole derivative compound that inhibits the enzymatic activity of TAFIa and enhances endogenous t-PAtriggered fibrinolytic activity (Fig. 1) . DS-1040 has shown highly potent and selective anti-TAFIa activity in nonclinical studies [18, 19] . DS-1040 is expected to enhance the thrombolytic activity of endogenous and exogenous t-PA, and hence may provide a thrombolytic effect without increasing bleeding risks. This first-in-human study assessed the safety and pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of DS-1040 in healthy young and elderly subjects.
Methods

Subjects
Healthy young (18-45 years) and elderly (65-75 years) males and females of non-childbearing potential with a body mass index of 18.5-30 kg m À2 at screening were eligible for enrollment. Subjects had to be in good healthas confirmed by medical examinations and laboratory tests -and have negative urine test results for drugs of abuse, and provide written informed consent prior to enrollment. Exclusion criteria included a history of any serious disorder, bleeding disorder, impaired renal function (creatinine clearance of < 80 mL min À1 in young subjects or < 60 mL min À1 in elderly subjects), recent major bleeding, abnormal bleeding time, or abnormal blood coagulation parameters. Anticoagulant or antiplatelet medications were not permitted for 2 weeks and 30 days, respectively, prior to and during the study.
Study design and treatments
This was a randomized, placebo-controlled, single-ascending-dose, single-blind, three-part, phase 1 study. Subjects were randomized 3 : 1 to receive either DS-1040 or placebo. The study protocol was approved by an appropriate Institutional Review Board. This study had three sequential parts, and each part had sequential cohorts in which ascending dose levels were assessed. The starting dose and the maximum dose were chosen on the basis of non-clinical toxicology data. In study part A, healthy young adults received single ascending doses of 0.1, 0.2, 0.4, 0.8, 1.6, 3, 6 or 12 mg of DS-1040 versus placebo; in part B, healthy elderly subjects received single doses of 3 or 6 mg of DS-1040 or placebo (Fig. S1) . In both parts A and B, assigned treatments were administered as short intravenous 30-min infusions. Part C assessed the effects of three ascending doses of 10, 20 or 40 mg of DS-1040 or placebo administered to young subjects as an initial 30-min infusion (loading dose: 10% of total dose), followed by a continuous intravenous infusion for 23.5 h (maintenance dose: 90% of total dose) (Fig. S1 ).
Study objectives
The primary objectives were to evaluate the safety of a single intravenous dose of DS-1040, including assessment of bleeding time and coagulation parameters, and to characterize the plasma and urinary pharmacokinetics of DS-1040, in parts A, B, and C. Other objectives included PD assessment of total TAFIa activity: 50% clot lysis; D-dimer activity; TAFI antigen levels in parts A, B, and C; and platelet aggregation in part C.
Study procedures and assessments
Subjects included in the study received a single intravenous dose of DS-1040 or placebo on day 1 under fasting conditions. Subjects remained in the clinic through day 3 in part A, until day 5 in part B, and until day 6 in part C. Follow-up assessments were performed on day 8 and day 11.
Safety was assessed by evaluating adverse events (AEs), bleeding time, physical examinations, vital signs, and clinical laboratory results, including coagulation parameters The Surgicutt bleeding time procedure was used to measure bleeding times (normal range within 2-8 min). Assessments were performed at baseline and at 30 min after infusion was started in parts A and B; an additional bleeding time measurement was performed at 24 h in part B. In part C, bleeding time was assessed at baseline (predose), at 24 h (end of infusion), and at 48 h following the start of infusion. Coagulation parameters were assessed 24 h before dosing and predose, and this was followed by multiple time assessments after initiation of infusion over a period of 48 h in part A, over a period of 96 h in part B, and over a period of 120 h in part C. Whole blood platelet aggregation was performed in part C with 10 lM ADP and 0.5 mM arachidonic acid assays.
Serial plasma and urine samples for PK assessment were collected predose and over a period of 48 h postdose in part A, over a period of 96 h postdose in part B, and over a period of 120 h postdose in part C. Pharmacokinetic analyses of DS-1040, in plasma (lower limit of quantification
) and urine (LLOQ < 10 ng L À1 ), were performed by use of a validated assay methodology with high-performance liquid chromatography coupled with tandem mass spectrometry. Assessed plasma PK parameters included maximum plasma concentration (C max ), time to reach maximum plasma concentration (t max ), area under the plasma concentration-time curve from the first to the last time point (AUC last ), area under the plasma concentrationtime curve extrapolated to infinity (AUC 0-inf ), terminal elimination half-life (t 1/2 ), and apparent total clearance (CL). The PK parameters calculated for DS-1040 in urine included cumulative amount of DS-1040 dose excreted into urine over the time interval (Ae), cumulative percentage of dose excreted as DS-1040 into urine over the time interval (Fe%), and renal clearance (CL R ).
The PD assessments for total TAFIa activity and analyses of clot lysis, TAFI antigen and D-dimer were performed predose and at multiple time points during and after infusion.
Biomarker methods
For the TAFI activity assay, the Pefakit TAFI plasmabased chromogenic assay validated at Medpace Research Laboratories (Cincinnati, OH, USA) was used to determine TAFI enzyme activity. Briefly, 10 lL of plasma was mixed with solution R1 (contains activating enzymes [thrombin/thrombomodulin] and protease inhibitors). This mixture was incubated for 3 min at 37°C, after which the R2 solution containing substrate was added.
The kinetic measurement at 405 nm was started, and the change in OD was monitored over a period of 5 min. The linear part of the curve was used to calculate the slope per minute (DE min
). The TAFIa activity was calculated by using the calibration curve obtained with the Pefakit TAFI Calibrator and Controls. The LLOQ was determined to be 11.4% of the standard plasma value, with a percentage coefficient of variation (CV) of < 5% interday and intraday variation.
The clot lysis assay established by Ammollo et al. [20] and Meltzer et al., [21] and validated at Intertek Pharmaceutical Services (San Diego, CA, USA), was based on a quantitative determination of fibrinolysis profiles in normal human sodium citrate plasma. Sixty microliters per well of sample (in duplicate) was added to assay plate(s). The plate was sealed and incubated for 30 min at 37°C. At the same time, the buffers used to prepare mixture A3 and t-PA were incubated at 37°C for 30 min. Mixtures and t-PA were immediately prepared with warmed buffer solutions. Mixture A3 was 20 FEU, with %CV of < 6% interday and intraday. TAFI antigen was assayed with the Hyphen BioMed (Sysmex America, Inc., Lincolnshire, IL, USA) ELISA kit, which enables the measurement of TAFI zymogen in plasma, and was validated at Intertek Pharmaceutical Services. The LLOQ was determined as 5.8% of the TAFI plasma standard value, with %CV of < 7% interday and intraday.
Statistical analyses
Results from subjects treated with placebo were pooled across the cohorts within each part. The mean DS-1040 plasma concentration-time profiles following each treatment regimen (dose and infusion duration) were presented graphically. DS-1040 plasma concentration values that were below the LLOQ at the beginning and end of a PK profile were set to zero, provided that the values below the LLOQ were not flanked by measurable concentrations. A value below the LLOQ that was flanked at adjacent time points by measurable concentrations was set to missing in the PK calculations. For continuous safety and PD variables, summary statistics were calculated. The PK parameters were derived by the use of non-compartmental analyses.
Results
Subject disposition and demographic characteristics
In total, 103 healthy subjects were randomized (3 : 1 randomization ratio for active treatment versus placebo) to three study parts (A, B, and C; Fig. S1 ). A total of 64 young (18-45 years) subjects were randomized to part A, with six subjects in each ascending DS-1040 dose cohort ( Fig. S1 ; eight cohorts, N = 48) and 16 subjects in the placebo group. A total of 15 elderly (65-75 years) subjects were randomized to part B, with two cohorts of six subjects each treated with either 3 or 6 mg of DS-1040, and three subjects treated with placebo. Of 24 young subjects randomized to part C, three cohorts with six subjects each received 10, 20 or 40 mg of DS-1040 (Fig. S1) , and six subjects received placebo. All randomized subjects received study treatment and had at least one postdose PD assessment, and were therefore included in the safety and PD analysis sets. In total, 48 subjects in part A, 12 in part B and 18 in part C received DS-1040 and were included in the PK analysis set. All randomized subjects completed this study.
In all cohorts in part A, subjects were aged 18-45 years and 92% were male. The elderly subjects participating in part B were aged 65-75 years and 40% were male. Subjects in part C were aged 18-45 years and 92% were male (Table S1 ).
Safety
AEs All treatment-emergent adverse events (TEAEs) during parts A, B and C of the study were mild or moderate in severity. The most frequently reported TEAEs included application site or contact dermatitis, ecchymosis, pain in extremities, and dyspepsia (Table S2) . None of the moderate TEAEs was deemed by the investigators to be related to study treatment, and no deaths, serious Fig. 2A) , but remained within the normal range below 10 min.
Bleeding time
No dose-related trend in bleeding time was observed in parts B or C (Fig. 2B, C) . In elderly subjects who received a 30-min infusion (part B), the mean (SD) bleeding times at baseline in the 3-mg and 6-mg cohorts were 4.63 min (2.12 min) and 3.92 min (1.06 min), respectively, with 5.83 min (1.13 min) in the placebo group, and remained similar postinfusion. The absolute changes from baseline in the mean (SD) Surgicutt bleeding time were À 0.42 min (2.05 min) (DS-1040 3 mg) and 0.50 min (0.61 min) (DS-1040 6 mg) at the end of infusion, and À 1.13 min (1.90 min) (DS-1040 3 mg) and À 0.33 min (1.10 min) (DS-1040 6 mg) at 24 h after the end of infusion. The mean changes in bleeding time in the placebo group were À 1.67 min (3.36 min) at the end of infusion, and À 2.33 min (1.28 min) at 24 h after the end of infusion.
In young subjects who received continuous infusion over a period of 24 h (part C), the mean (SD) bleeding times at baseline were 4.75 min (2.22 min), 4.79 min (1.92 min) and 5.38 min (1.13 min) in the 10-mg, 20-mg and 40-mg DS-1040 cohorts, respectively, and 3.50 min (2.06 min) in the placebo group. At the end of the 24-h infusion, the mean (SD) bleeding times were 4.67 min Coagulation parameters In all three parts of the study, the changes from baseline to the end of treatment, and to 24 h after treatment, in the mean coagulation parameters such as PT, APTT and fibrinogen, were minor and clinically non-significant. No clear dose-related trend was noted (Table S3) . Administration of DS-1040 had no clinically significant effect on platelet aggregation at any dose level in part C (Table S4) .
PK parameters
In young subjects who received a short 30-min infusion (part A), the mean plasma DS-1040 concentration increased with increasing doses of DS-1040 (Fig. 3A) . Similarly, mean C max , AUC last , and AUC 0-inf progressively increased over the dose range of 0.1-12 mg of DS-1040 (Table S5 ). The mean (SD) C max ranged from 7.9 ng mL À1 (1.9 ng mL À1 ) in the 0.1-mg dose cohort to 1102.3 ng mL À1 (179.1 ng mL
À1
) in the 12-mg dose cohort (Table S5 ). The median t max ranged from 0.500 h to 0.667 h in all dose cohorts. The mean (SD) AUC 0-inf ranged from 11.8 ng h mL À1 (1.4 ng h mL À1 ) in the 0.1-mg dose cohort to 2225.5 ng h mL À1 (227.1 ng h mL
) in the 12-mg dose cohort (Table S5 ). The variation in (apparent) total CL and t 1/2 across the dose levels (Table S5) was probably attributable to quantification of the plasma concentration of DS-1040 at doses of DS-1040 below 3 mg being limited by the assay's LLOQ. The mean (apparent) CL R and percentage of the DS-1040 dose recovered in the urine at 48 h postdose varied across dose cohorts, with no consistent dose-related trends being seen (Table S5 ). The mean percent urinary recovery of the DS-1040 dose ranged from approximately 44-93%, and mean (SD) CL R ranged from 3.3 (1.5) L h À1 to 7.1 (3.6) L h À1 (Table S5 ).
In healthy elderly subjects (part B), the mean plasma concentrations of DS-1040 increased with DS-1040 dose and were higher than the concentrations reached in healthy young subjects treated with the same doses of DS-1040 ( Fig. 3B; compare with Fig. 3A) . Mean exposure parameters such as C max , AUC last and AUC 0-inf increased in proportion to DS-1040 dose, and were generally higher than or similar to those in young subjects, consistent with the trend observed for plasma concentration-time data (Table S5) . Furthermore, the mean total CL was lower, and t 1/2 was prolonged in elderly subjects as compared with young subjects in part A (Table S5 ). The mean (urinary) percentage of the DS-1040 dose recovered by 72 h postdose was approximately 69% for both 3-mg and 6-mg DS-1040 doses. The mean (SD) CL R ranged from 2.
) in the 6-mg dose cohort, and was reduced as compared with the mean CL R values achieved for 3-mg and 6 mg DS-1040 doses in young subjects (4.7 L h À1 and 4.6 L h À1 , respectively; Table S5 ).
During continuous infusions of DS-1040 in part C, plasma concentrations of DS-1040 increased doseproportionally and reached an initial peak at 0.5 h, which was followed by a stable plasma DS-1040 concentration, which was reached by 4 h and maintained throughout the 24-h infusion (Fig. 3C) . Mean exposure parameters such as C max , AUC last and AUC 0-inf increased proportionally with increasing DS-1040 dose (Table S5 ), but mean CL and t 1/2 values remained comparable across doses and similar to those reported in part A for the 12-mg dose (Table S5 ). The mean (urinary) percentage of the DS-1040 dose recovered by 96 h postdose ranged from 78% to 80% across doses. Mean CL R values were similar across doses (Table S5) .
PD parameters
TAFIa activity On the basis of the PK/PD data from this study, the estimated IC 90 for inhibition of TAFIa activity is 7.00 ng mL À1 . In all study parts, TAFIa activity decreased as dose increased, reaching minimal values at 30 min, which corresponded to the end of infusion in parts A and B and the end of the loading dose administration in part C ( Fig. 4A-C ; Table S6 ). No change in TAFIa activity was noted in the placebo groups ( Fig. 4A-C) . In part A, the maximal decrease in the mean (SD) change from baseline occurred at the end of the 30-min infusion, and ranged from À 5.58% (5.00%) (DS-1040 0.1 mg) to À 91.33% (18.64%) (DS-1040 12 mg). A similar trend was observed in part B. The mean TAFIa activity gradually returned to baseline levels at 24 h postdose in parts A and B (Fig. 4A, B) . In part C, the largest decrease in TAFIa activity was observed at 30 min after the start of infusion, and was maintained throughout the duration of the continuous infusion period. TAFIa activity gradually recovered, and reached predose levels at 24 h after the end of infusion. A clear DS-1040 dose-related and treatment duration-dependent decrease in TAFIa activity demonstrated an extended pharmacologic effect with continuous infusion (Fig. 4C ).
Fifty percent clot lysis time On the basis of the PK/PD data obtained in this study, the estimated IC 90 for clot lysis is 38.20 ng mL À1 . In all parts of this study, the 50%
clot lysis time showed a DS-1040 dose-related decrease ( Fig. 5A-C ; Table S6 ). In parts A and B, the mean 50% clot lysis time decreased with the ascending DS-1040 doses, with the maximal decrease being seen at the end of the 30-min infusion. Thereafter, the mean 50% clot lysis time gradually returned to predose baseline levels at 24 h postdose (Fig. 5A, B) . In part C, the greatest reduction in the mean 50% clot lysis time was observed at 30 min after the start of infusion, and it remained reduced until 1 h after the end of the continuous infusion, when it began to recover, and it returned to predose levels by 24 h following the end of infusion (Fig. 5C ).
D-dimer levels Increases in D-dimer levels were observed after DS-1040 treatment in some individuals. However, dose dependency could not be demonstrated, because 20% and 30% of subjects in parts A and C, respectively, had undetectable D-dimer levels predose (below the LLOQ of 0.17 mg L
À1
). All healthy elderly subjects in part B had detectable levels of D-dimer both predose and postdose. The time course of mean D-dimer levels among elderly subjects in part B is shown in Fig. S2 . In part C, increases in D-dimer levels were also observed in several subjects, starting at 1 h after the start of infusion, and lasting for up to 48 h after the end of infusion.
TAFI antigen levels Mean TAFI antigen activity levels did not show any clear trend regarding a dose-related effect. At the individual subject level, TAFI antigen activity fluctuated postdose as compared with baseline levels (Fig. S3A-C) . From these results, no clear DS-1040 treatment effect could be determined.
Discussion
Several novel intravenous thrombolytic agents are currently in clinical development, with the aim of overcoming the limitations of current standard-of-care treatments for AIS and VTE, mainly the narrow time window of t-PA treatment and bleeding complications associated with thrombolytic therapy [8, [22] [23] [24] . Therapeutics enhancing fibrin degradation through the plasminogen activator (PA) pathway, such as urokinase [25] , PA derived from human kidney cells, and reteplase [26, 27] , a recombinant PA derived from rt-PA, were developed to improve the rates of reperfusion with rt-PA and recanalization rates after intraarterial thrombolysis. The newer generation of similar agents includes tenecteplase -a genetically modified form of native t-PA with an increased half-life and fibrin specificity [28, 29] -and desmoteplase, a non-neurotoxic PA with high fibrin specificity and a long terminal half-life isolated from vampire bat saliva [30] [31] [32] . These agents are being evaluated in clinical trials, but the clinical evidence collected thus far does not unequivocally support their superiority to rt-PA [33, 34] . Other new therapeutics include fibrinogendepleting serine proteases -such as ancrod and defibrasethat restore blood flow by reducing the amount of fibrinogen in blood plasma. However, despite effective reduction of fibrinogen levels, these agents failed to provide clinical benefit, and have been reported to be associated with an increased risk of symptomatic intracranial hemorrhage [35] . DS-1040 promotes fibrinolysis via inhibition of TAFIa [18] , and represents the first thrombolytic agent of this type. In a rat study, in contrast to exogenously administered t-PA, DS-1040 did not prolong bleeding time, even when administered at doses 480-fold higher than the pharmacologically active dose in the same species [19] . This first-in-human study evaluated the safety, tolerability and PK and PD parameters of single ascending doses of DS-1040 in healthy young and elderly subjects, and compared the DS-1040 profile following a short 30-min intravenous infusion with that following continuous infusion over a period of 24 h. Overall, single doses of DS-1040 (dose range of 0.1-40 mg) were well tolerated. An increase in bleeding time of 40-66% was observed in young subjects who received a short infusion of DS-1040 doses of 3 mg, 6 mg, and 12 mg. These changes, however, were not deemed to be clinically significant, as all bleeding time values remained within the normal range, below 10 min. No change in bleeding time was observed in elderly subjects or young subjects who received a 24-h continuous infusion resulting in similar or higher exposures. These results are reassuring, despite the fact that bleeding time is a crude assessment of bleeding risk; further clinical evidence is needed to determine the actual risk of bleeding for DS-1040 in human subjects. No change in coagulation parameters or platelet aggregation occurred after treatment with DS-1040.
Exposure of DS-1040 increased with increasing doses, and urinary excretion was identified as the major elimination route. Slightly higher exposure levels were observed in elderly subjects than in young subjects, owing to prolonged systemic elimination and decreased renal clearance. Importantly, DS-1040 caused a concentration-dependent decrease in TAFIa activity and 50% clot lysis time in both young and elderly subjects receiving DS-1040 at the same dose levels. Endogenous fibrinolysis was evidenced by increased D-dimer levels in some individuals, but dose dependency could not be established, owing to the lack of detectable levels of D-dimer in many subjects.
In summary, the safety profile and PK/PD properties of DS-1040 in healthy volunteers indicate that DS-1040, a fibrinolysis enhancer, has the potential to provide 
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